Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dacomitinib Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 13/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 8/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | MC3R | P41968 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dacomitinib Anhydrous SCHEMBL33147 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29354322 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL30115337 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL25637 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29396914 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL25098 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL33136 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL22498351 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29445648 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29359689 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355330-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | Genentech, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| CN-117479943-A | EGFR inhibitors and PERK activators in combination therapies and use thereof for treating cancer | 基因泰克公司 | 2024-01-30 | — | — | CN | claimed |
| WO-2022265950-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | GENENTECH, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025238176-A1 | COMBINATIONS OF EGFR/ERB AND BET INHIBITORS FOR GASTRIC CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | disclosed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2025106901-A1 | COMBINATION CANCER THERAPIES WITH A KRAS MODULATOR AND AN RTK-MAPK PATHWAY INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-112955137-B | Combination therapy | 米拉蒂治疗股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025034919-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20230165861-A1 | USE FOR PROTECTING OR MITIGATING RADIATION DAMAGE, AND FOR PREVENTING OR TREATING PULMONARY FIBROSIS | KOREA INST RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2023-06-01 | — | — | US | disclosed |
| WO-2023059596-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-04-13 | — | — | WO | disclosed |
| CN-115776889-A | EGFR TKI for treatment of non-small cell lung cancer | 阿斯利康(瑞典)有限公司 | 2023-03-10 | — | — | CN | disclosed |
| WO-2022265950-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | GENENTECH, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20220365074-A1 | METHODS AND SYSTEMS FOR DETERMINING VIRUSES SUCH AS CORONAVIRUSES USING pH | ANALIZA, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-4048273-A1 | NOVEL DRUG COMBINATIONS FOR TREATMENT OF A CARCINOMA | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-08-31 | — | — | EP | disclosed |
| CN-114980883-A | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114728000-A | Novel pharmaceutical combination for the treatment of cancer | 荷兰癌症研究所-安东尼·范·雷文虎克医院基金会 | 2022-07-08 | — | — | CN | disclosed |
| CN-112004845-B | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate, and semiconductor device | 三菱瓦斯化学株式会社 | 2022-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | EGFR 2414/4885ERBB2 1580/4885ERBB4 1681/4885 |
| US-20230165861-A1 | USE FOR PROTECTING OR MITIGATING RADIATION DAMAGE, AND FOR PREVENTING OR TREATING PULMONARY FIBROSIS | CFTR, MMP1, AQP1 | EGFR 1780/4885ERBB2 4832/4885ERBB4 4789/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | EGFR 2414/4885ERBB2 1580/4885ERBB4 1681/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | EGFR 2095/4885ERBB2 1560/4885ERBB4 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.